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To: (1) estimate the prevalence of clinically significant emotional distress in patients attending a cancer outpatient department and (2)
determine the associations between distress and demographic and clinical variables, we conducted a survey of outpatients attending
selected clinics of a regional cancer centre in Edinburgh, UK. Patients completed the Hospital Anxiety and Depression Scale (HADS)
on touch-screen computers and the scores were linked to clinical variables on the hospital database. Nearly one quarter of the cancer
outpatients 674 out of 3071 (22%; 95% confidence interval (CI) 20–23%) met our criterion for clinically significant emotional distress
(total HADS score 15 or more). Univariate analysis identified the following statistically significant associations: age o65, female
gender, cancer type and extent of disease. Multivariate analysis indicated that age o65 (odds ratio 1.41; 95% CI 1.18–1.69), female
gender (odds ratio 1.58; 95% CI 1.31–1.92) and active disease (odds ratio 1.72; 95% CI 1.43–2.05) but not cancer diagnosis, were
the independent predictors of clinically significant emotional distress. Services to treat distress in cancer patients should be organised
to target patients by characteristics other than their cancer diagnosis.
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Emotional distress refers to a continuum of psychological
symptoms varying in severity (Carlson and Bultz, 2003). Reported
prevalence rates of clinically significant emotional distress, defined
here as cases of depression and anxiety, in cancer outpatients have
varied from 15 to 42% (see Table 1). Despite the large number of
studies published, we still have only limited information about the
risk factors for clinically significant emotional distress in out-
patients attending cancer centres. This is because the majority of
published studies have either been small or of patients with
specific cancer types. Of the published studies of outpatient
samples with mixed cancer types only two have specifically
reported the associations of clinically significant emotional
distress in samples of more than 500 patients (Pascoe et al, 2000;
Zabora et al, 2001) and none have studied patients attending
clinics serving a geographically defined population. More data is
therefore needed to best target resources for the management of
emotional distress in cancer centres.
We therefore aimed to measure the prevalence of clinically
significant emotional distress and to determine its demographic
and clinical associations in a large sample of outpatients with a
variety of cancer types attending a regional cancer centre.
MATERIALS AND METHODS
Setting
The study took place in the Edinburgh Cancer Centre, which is a
regional, tertiary, cancer centre and is the sole provider for
specialist cancer services to a geographically defined population of
approximately 1.5 million people in the South East of Scotland UK.
Sample
We included consecutive follow-up attenders over the age of 18 at
the following diagnosis based cancer clinics: colorectal, breast,
gynaecological, genitourinary, sarcoma, melanoma and mixed
cancers (but not lung, upper gastrointestinal, head and neck and
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shaematological cancer services as the screening system was
not operating in these clinics). We excluded patients who
were attending the cancer centre for the first time, those screened
within the previous month and also those who were unable
to respond because of being too ill, unable to read English or
who had major communication or cognitive problems. Recruit-
ment took place over 18 months from June 2003 to December
2004.
Design
Cross-sectional survey linking self-report and clinical data.
Procedure
A semiautomated symptom screening service had been established
in the clinic in order to provide clinical information on
patients’ physical and psychological symptoms to their
cancer team. As part of this system all individuals attending
follow-up outpatient clinics were invited to complete the Hospital
Anxiety and Depression Scale (HADS) (Zigmond and Snaith,
1983). After the patient had checked in at reception, the
questionnaire was administered on touch-screen computers
situated in a dedicated suite adjacent to the consultation rooms,
and the results were made available to the Oncologist before the
consultation. The use of computers in screening for quality of life
and psychological distress in patients with cancer has been found
to be an acceptable and efficient way to obtain self-report
information (Allenby et al, 2002).
Ethical approval
As the data were collected as part of the clinical service individual
patient’s consent was not obtained. Approval for the aggregated
anonymised data to be reported was obtained from the local
research ethics committee.
Measures
Emotional distress was measured using the HADS. This scale was
chosen over others because it is well established, widely used,
acceptable to patients and has been extensively used in both cancer
and non-cancer patients. The HADS is a self-rated 14-item
questionnaire specifically designed for patients with medical
illness. It has depression and anxiety subscales with seven items
each. These two subscales correlate highly and HADS scores are
frequently analysed as a single scale (Bjelland et al, 2002).
Individual items are rated on a four-point scale (0–3), resulting
in maximum scores of 21 on each subscale and a total maximum
score of 42. Patients are asked to report symptoms over the
previous week.
Clinically significant emotional distress was defined as a total
HADS score of 15 or above. This cutoff score was reported by
Ibbotson et al (1994) to be the best for identifying patients likely to
have an interview based diagnosis of depressive or anxiety
disorder. The reliability, validity and factor structure of the HADS
has been established in a variety of clinical populations (Moorey
et al, 1991; Johnston et al, 2000; Mykletun et al, 2001; Smith et al,
2002) and validated in this population of cancer patients. We
found that a cutoff of 15 or above on the total HADS score gave a
Table 1 Studies of prevalence of clinically significant emotional distress and its associations in cancer outpatients
Authors and year of
publication (country) Sample characteristics (n)
Self-rated measure
a
(cutoff used)
General
distress Anxiety Depression
Examined
clinical
associations
(yes/no)
Balderson and Towell 2003
(UK)
Prostate (94) HADS (total X15) 38% y
Berard et al 1998 (S Africa) Breast, head and neck,
lymphoma (456)
HADS (DX8) 14% n
Bisson et al 2002 (UK) Prostate (88) HADS (A X11, DX11) 8% 0% y
Bradley et al 2005 (Canada) Advanced mixed cancers,
receiving radiotherapy (1296)
ESAS (total X4) 29% 25% y
Dahl et al 2005 (Norway) Testicular (1408) HADS (A X8, D X8) 19.2% 9.7% y
Fallowfield et al 2001 (UK) Mixed cancers (2297) GHQ12 (total X4) 36.4% n
Ford et al 1995 (UK) Mixed cancers, newly
diagnosed (117)
GHQ-30 (cutoff not
specified)
30% n
HADS (A X11, DX11) 26% 7%
Grassi et al 2004 (Italy) Mixed cancers (227) HADS (AX11, DX11) 17% 9% n
Hahn et al 2004 (USA) Mixed cancers receiving
radiotherapy (124)
BDI-II (total X14) 15% n
Hopwood et al 1991 (UK) Advanced Breast cancer (81) HADS (AX11 or DX11) 42% n
Ibbotson et al 1994 (UK) Mixed cancers (513) HADS (total X15) 17% n
Norton et al 2004 (USA) Ovarian, mostly advanced
disease (143)
BDI (cutoff not specified) 20% y
Pascoe et al 2000 (Australia) Mixed cancers (504) HADS (A X11, DX11,
total X8)
30.6% 11.5% 7.1% y
Razavi et al 1992 (Belgium) Lymphoma (117) (self-rated) DSM II-R 36.8% n
Sharpe et al 2004 (UK) Mixed cancers (3938) HADS (total X 15) 23% n
Yan and Sellick 2004 (China) Gastro-intestinal, newly
diagnosed on active treatment
(146)
BDI-13 (total X5) 27.4% y
Zabora et al 2001 (USA) Mixed cancers (4496) BSI (global severity index or
total symptom score X63
on either BSI subscale)
35% 24.1% 18.7% y
BDI-II and BDI-13 variations on the Beck Depression Inventory; BSI¼Brief Symptom Inventory;
aBD1, ESAS¼Edmonton Symptom Assessment Scale; GHQ-30 and is the
General Health Questionnaire–GHQ-30 items; HADS¼Hospital Anxiety and Depression Scale and 12 items. DSMII-R is interview is the Structured Clinical Interviews for DSM
Axis 1 Disorders; n¼no; y¼yes. A¼anxiety subscale; D¼depression subscale.
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ssensitivity of 0.87 (95% confidence interval (CI) 0.70–0.95), a
specificity of 0.85 (95% CI 0.81–0.89) and a positive predictive
value of 0.35 for Major Depressive Disorder (Walker et al,i n
press). We also analysed the depression and anxiety subscales
separately using the recommended cutoff scores (Bjelland et al,
2002) of nine or more on the anxiety subscale and eight or more on
the depression subscale.
The cancer centre clinical database contained data on patients’
demographic and clinical characteristics including cancer type,
clinical staging of disease and treatment received. The patients’
clinical data relevant to the time of the selected screening event
was anonymised and matched to the HADS score using a unique
patient identification number and date of birth. The primary
cancer type was classified according to the site of origin. In cases
with more than one cancer type, the cancer that was dominating
treatment at the time of screening was recorded. Disease status was
classified into ‘disease free’ and ‘active disease’. Treatment status
was determined by identifying the treatment the patient had
received within 2 months before the screening date and categorised
as ‘no anti-cancer treatment’, ‘receiving hormone treatment’ or
‘receiving chemotherapy and/or radiotherapy treatment’ (see
Appendix A-online). The accuracy of the data recorded on the
electronic database was checked against patients’ paper case notes
in a 5% random sample and good agreement (97%) found.
Analysis
The statistical analysis first compared the characteristics of eligible
patients on whom we had complete data with those patients with
missing HADS data or who had refused screening in order to
assess to what extent the sample was representative of the eligible
population. The HADS total and depression and anxiety subscale
scores were described by calculating the medians and interquartile
ranges.
The prevalence of clinically significant emotional distress, and
depression and anxiety separately (and the 95% CI around these
estimates) were calculated using the cutoff scores described above.
The associations of clinically significant emotional distress with
cancer type, extent of disease, treatment, age and gender were then
examined using univariate logistic regression. Multivariate logistic
regression, using the method of stepwise selection, was subse-
quently applied to identify independent predictors of clinically
significant emotional distress.
All statistical analysis were carried out using SAS version 9.1
software, with Stata version 9 for calculating the CI for prevalence
estimates.
RESULTS
Sample
Data were available on 3071 patients, representing 85% of eligible
clinic attendees. The details of how the final sample was derived
and the reasons for missing data are shown in Figure 1.
Table 2 shows the cancer characteristics of the final sample
together with those for the patients whose data were missing or
incomplete. There were modest differences between these groups
in all variables other than treatment received. These differences,
especially disease severity, mainly reflect the difficulty obtaining
screening data from very ill patients. The large number of patients
classified as disease-free, reflects the number attending for post
treatment follow-up.
HADS score
The distribution of the total HADS scores is shown in Figure 2. As
can be seen, the distribution is skewed towards lower scores (less
distress).
The median scores for the HADS total score and the two
subscales together with prevalence rates and 95% CIs are shown in
Table 3.
*Patients ‘not included’ had communication difficulties, cognitive impairment, or 
were very ill. 
Patients with HADS
and clinical data
 n = 3071
Eligible patients attending the
selected outpatient clinics
n = 3631
Refused n = 283 (7.8%) 
Missed n = 274 (7.5%)
HADS data incomplete n = 3 
Follow-up patients attending the 
selected outpatient clinics 
n = 3826 
Not included* n = 62 
(1.6%)
Clinical data missing n = 133 
(3.5%)
Figure 1 Flow diagram of patients surveyed indicating derivation of final sample.
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sUsing univariate analysis, we examined associations between
cases of clinically significant emotional distress and the pre-stated
demographic variables and cancer characteristics (Table 4). This
analysis indicated that patients, who were female, had active
disease and were aged o65 were more likely to be cases. There was
also an association with cancer type.
Multivariate logistic regression analysis was used to identify the
most important independent predictors of clinically significant
emotional distress and the results are shown in Table 5. Having
accounted for the effect of age, gender and extent of disease, no
other factors emerged as significant predictors. Being female and
having active disease both increase the likelihood of distress,
whereas being over 65 reduces the likelihood. Notably cancer type
was not a predictor.
The associations with clinically significant anxiety and depres-
sion were similar to those with clinically significant emotional
distress (depression or anxiety). Only gender and extent of disease
were independent predictors for cases of clinically significant
depression whereas age was also a predictor for anxiety.
DISCUSSION
Main finding
Almost a quarter (22%; 95% CI 20–23%) of our sample of
outpatients at a cancer centre attending colorectal, breast,
gynaecological, genitourinary, sarcoma, melanoma and mixed
cancer clinics had clinically significant emotional distress defined
as a total HADS score of 15 or more. Furthermore, these cases were
not uniformly distributed in the sample; independent predictors of
distress were being female, having active disease, and being aged
o65. The type of cancer was associated with distress in the
univariate analysis but did not emerge as an independent predictor
in the multivariate analysis.
Limitations
These findings must be set in the context of a number of
limitations. The first category concerns the patient sample: (a) we
did not survey all the clinics in the cancer centre. Several cancer
clinics including lung, upper gastrointestinal, head and neck and
haematological cancers were not included. As other studies have
reported a high prevalence of emotional distress in patients with
these cancers (Zabora et al, 2001; Montgomery et al, 2003), the
findings presented may have underestimated the prevalence of
clinically significant emotional distress in the whole cancer centre;
(b) not all patients attending the cancer centre completed the
HADS screening. New outpatient attenders were excluded at the
request of the clinicians. In addition, a number of patients did not
complete the screening for reasons previously detailed and there
were modest but statistically significant differences between the
analysed sample and those on whom we had incomplete data. The
patients who did not complete the screening were more likely to be
younger, male, with testicular cancer or patients with advanced
Table 2 Demographic and clinical characteristics of the eligible patients
with complete data and those with incomplete data (n¼3631). Numbers
shown are percentages (n) except when specified
Variable Complete data Incomplete data P-value
a
Total 3071 560
Age (continuous) 0.0113
Median (range) 62.0 (18.2 to 93.1) 63.5 (21.5–92.9)
Age (categorical) 0.0149
o65 58 (1793) 53 (296)
X65 42 (1278) 47 (264)
Gender 0.0016
Male 34 (1048) 41 (230)
Female 66 (2023) 59 (330)
Cancer type 0.0004
Breast 35 (1084) 31 (172)
Bowel 15 (458) 14 (81)
Prostate 12 (359) 12 (68)
Ovarian 10 (305) 8 (43)
Other
gynaecological
10 (313) 9 (48)
Testicular 8 (247) 13 (70)
Other
b 10 (305) 14 (78)
Extent of disease 0.0049
Disease free 67 (2068) 61 (343)
Active disease 33 (1002) 39 (217)
Unknown
c 0.03 (1)
Treatment 0.0861
No anti-cancer
treatment
55 (1684) 58 (326)
Hormone 17 (518) 18 (101)
Chemo and/or
radiotherapy
28 (869) 24 (133)
aExcept for age (continuous), all P-values are from a chi-square test. Age (continuous)
is compared using the Mann–Whitney U-test. The number of unknown records is
not included as part of the chi-square test.
bThe group ‘other’ contained the following
cancers: lung, n¼82; melanoma, n¼63; sarcoma, n¼55; kidney, n¼28; primary
peritoneal, n¼18; bladder, n¼14; head and neck, n ¼11; upper GI, n¼6;
pancreatobiliary, n ¼6; haematology, n¼3; penis, n¼3; adrenal, n¼2; epididymis,
n ¼1; and ‘unknown primary cancer, n¼13.
cInsufficient clinical data available to
determine extent of disease.
15.0
10.0
5.0
12.5
7.5
2.5
P
e
r
c
e
n
t
0
048 1 2 1 6 2 0
Total HADS score
24 28 36 32
Figure 2 Distribution of total HADS scores of sample (n¼3071).
Table 3 HADS scores (n¼3071)
Scale
Median
(range)
cutoff
criterion
Sample
prevalence
Percent
(number)
Population
prevalence
estimate 95%
Confidence
interval
Total HADS 8 (0–38) X15 22 (674) 20–23
Anxiety
subscale
5 (0–21) X9 23 (704) 21–24
Depression
subscale
3 (0–21) X8 16 (482) 14–17
HADS¼Hospital Anxiety and Depression Scale.
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sdisease. Despite these limitations, this study is the largest survey of
clinically significant emotional distress and its associations yet
conducted in a sample of mixed cancer outpatients referable to a
geographically defined population.
The second category of limitations concerns the measures used:
our definition of ‘clinically significant emotional distress’ was
based on a self-rated questionnaire and not on a clinical interview.
This means that many patients with transient distress, who would
not receive duration-based diagnoses from a clinical interview, will
have been included. A diagnostic interview that interrogated
patients about the timing of symptoms would be expected to
produce a lower prevalence estimate of cases. There has also been
some controversy about the validity of the HADS at the
recommended cutoff scores in detecting distress in patients with
all cancer types and at all disease stages (Ibbotson et al, 1994; Hall
et al, 1999). The scores we used were based on the best available
data and on our own validation study. Furthermore, the use of
cutoff scores allowed us to estimate the actual prevalence of
clinically significant emotional distress and not just mean values in
the sample.
Relationship of findings to other studies
There have been few studies with which our findings can be
compared directly because of the variety of measures and criteria
that have been used (a list is given in Table 1) and the range of
populations studied. Some comparison can be made with the two
large studies of outpatients with mixed cancers that reported the
prevalence of ‘cases’ of distress and its associations. Pascoe et al
(2000) in an Australian study used the HADS at a lower cutoff for
clinically significant distress and higher cutoffs for anxiety and
depression and found comparable prevalence rates of 31% for
distress, 12% anxiety and 7% depression. Zabora et al (2001) in a
study from the US used the Brief Symptom Inventory, and
reported case prevalence rates of 35% for distress, 24% anxiety and
19% depression. Pascoe et al (2000) found that being female, aged
o65 years and having a reduced activity status (which may be
regarded as measuring a similar concept to advanced disease) were
associated with distress, whereas Zabora et al (2001) found
younger age and lower income to be associated with higher levels
of distress but did not find an association with gender. Neither
found a strong association with disease type. The results reported
here confirm that in a large sample from a geographically defined
population from the UK cancer type is not an important predictor
of emotional distress and that female gender, younger age and
severity of disease are.
Implications
Despite the large number of studies that have been published
studying emotional distress in cancer patients, general conclusions
have been difficult to draw because of their methodological
limitations and diverse measures. It would be helpful if future
studies adopted similar measures and agreed cutoff scores for
clinical significance to allow meaningful comparison between
them.
The findings of this survey highlight the prevalence of clinically
significant emotional distress in an outpatient cancer population
and consequently the need for services to attend to this. Although
Table 4 Univariate analysis association with clinically significant emotional distress, anxiety and depression with demographic and clinical variables
(n¼3071). Numbers shown are percentages (n) except when specified
Variable
Anxiety (score X9)
%( n)
Depression (score X8)
%( n)
Distress (total score X15)
%( n)
Odds ratio for distress
(95% CI) P-value
Age (categorical) 0.0007
o65 28 (493) 15 (273) 24 (432) 1.00
X65 17 (211) 16 (209) 19 (242) 0.74 (0.62–0.88)
Gender o0.0001
Male 16 (168) 12 (124) 17 (177) 1.00
Female 27 (536) 18 (358) 25 (497) 1.60 (1.32–1.94)
Cancer type o0.0001
Breast 26 (283) 18 (192) 23 (252) 1.22 (0.93–1.6)
Bowel 16 (71) 14 (62) 20 (91) 1.00
Prostate 14 (49) 13 (46) 15 (53) 0.70 (0.48–1.01)
Ovarian 30 (92) 18 (54) 27 (83) 1.51 (1.07–2.12)
Other gynaecological 27 (85) 15 (47) 23 (72) 1.21 (0.85–1.71)
Testicular 18 (45) 7 (18) 16 (39) 0.76 (0.50–1.14)
Other 26 (79) 21 (63) 28 (84) 1.53 (1.09–2.15)
Extent of disease o0.0001
Disease free 21 (443) 13 (264) 19 (395) 1.00
Active disease 26 (260) 22 (217) 28 (278) 1.63 (1.36–1.94)
Treatment 0.0716
No anti-cancer treatment 22 (366) 14 (230) 21 (346) 1.00
Hormone 27 (138) 19 (99) 25 (130) 1.30 (1.03–1.63)
Chemo and/or radiotherapy 23 (200) 18 (153) 23 (198) 1.14 (0.94–1.39)
Table 5 Multivariate analysis for independent predictors of clinically
significant emotional distress (n¼3071)
Variable
Distressed
%( n)
Not distressed
%( n)
Odds ratio
(95% CI) P-value
Age (categorical) 0.0002
o65 24 (431) 76 (1361) 1.00
X65 19 (242) 81 (1036) 0.71 (0.59–0.85)
Gender o0.0001
Male 17 (176) 83 (871) 1.00
Female 25 (497) 75 (1526) 1.58 (1.31–1.92)
Extent of disease o0.0001
Disease-free 19 (395) 81 (1673) 1.00
Active disease 28 (278) 72 (724) 1.72 (1.43–2.05)
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ssome diagnosis-based cancer services will have a higher prevalence
of emotional distress than others, the analysis of independent
predictors implies that if efforts to identify cases are to be targeted,
variables other than cancer type are likely to be most useful.
General cancer centre based psychological services may be more
efficient than diagnosis based ones.
CONCLUSION
The results of this study emphasise the need to develop services to
improve the management of emotional distress in outpatient
cancer services and suggest how these may be best targeted.
Further studies are now required to design and test appropriate
therapeutic interventions for patients who have been identified as
having clinically significant emotional distress.
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Appendix A
Cancer and treatment status classifications
Cancer diagnosis Owing to the small numbers of patients in some
categories, the primary cancer types were grouped into seven
major categories: breast, testicular, ovarian, prostate, bowel
(included rectal, colon and anal sites of origin), other gynaecolo-
gical (included cervical, uterine, vulva and vaginal sites of origin),
and others (included lymphoma, head and neck, lung, upper
gastro-intestinal, melanoma, brain and central nervous system,
kidney, adrenal gland, bladder, epididymis, sarcoma, primary
peritoneal, basal cell and unknown primary cancers).
For the majority of the patients, their primary cancer type was
classified according to the site of origin. The only exceptions were:
(1) Melanoma. This was classified as melanoma regardless of the
site of origin
(2) Germ cell tumour in regions other than the gonads (e.g.
mediastinal) was classified in men as testicular and in women
as ovarian cancer.
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sThose patients who had more than one primary cancer type
were classified according to the cancer they were being treated for
at the time of screening. If they were being treated for more than
one malignancy concurrently, they were classified according to the
cancer that was dominating their treatment at the time of
screening.
Those patients, who were disease-free and on no treatment for
any of their previous cancers, were classified according to their
most recently diagnosed cancer.
Cancer status at time of screening Patients were classified
according to their clinically detectable cancer status at the time of
screening. The categories were ‘disease-free’ and ‘active disease’ or
‘unknown’. Some clinical situations could be classified in more than
one way. For clarity, these are outlined under the appropriate section.
Disease-free
  Undergoing post surgical adjuvant radiotherapy/chemotherapy/
hormone therapy with no clinically detectable residual disease.
  After completion of primary radical chemotherapy or radio-
therapy given with curative intent and no documented residual
disease or recurrence (i.e. early anal cancer after radical
chemoradiation and stage 3 ovarian cancer after chemotherapy
with normal serum markers)
  Metastatic cancer which had been surgically removed and no
documentation of recurrence (e.g. liver metastases from bowel
cancer, which were removed after chemotherapy and partial
hepatectomy)
Active disease (local and metastatic disease categories combined)
Local disease
  Clinically detectable local disease or regional lymph node
metastases
  Undergoing primary chemotherapy or radiotherapy with
curative intent, for example, early anal cancer
  Undergoing neo-adjuvant chemotherapy/radiotherapy/hor-
mone treatment before surgery (unless metastatic disease)
Metastatic
  Metastases to organs or distant lymph nodes
  Stage 3 ovarian cancer undergoing primary or post-surgical
chemotherapy at the time of screening (because it is assumed
there is residual disease in the abdominal cavity)
  Relapsed ovarian cancer
  Primary lung cancer with disease in more than one lobe of lung
because it was not treated with curative intent
  Breast cancer with supra-clavicular nodes
Unknown When it was not clear what the cancer status was at the
time of screening
Treatment status at the time of screening Treatment status was
described according to what treatment had been received within
the 2 calendar months before screening: no anti-cancer treatment,
hormone treatment, chemotherapy, radiotherapy, surgery or any
combination of these (although this does not automatically imply
that they were concurrent). These were collapsed into the three
groups presented in the paper: (1) no anti-cancer treatment (which
included those who had had surgery); (2) hormone treatment and
(3) chemotherapy and/or radiotherapy treatment. Those who had
received two treatment modalities within the last 2 months were
allotted to the most clinically dominant category according to the
following ranking: chemo/radiotherapy 4hormones 4surgery, for
example, those who had received both surgery and chemotherapy
were assigned to the chemo and/or radiotherapy treatment group.
No distinction was made between the dose and fractionation of
radiotherapy administered; patients were classed as undergoing
radiotherapy provided at least one fraction of treatment had been
administered within the previous 2 calendar months.
The arbitrary 2-month cutoff was made on the basis that
patients’ symptoms might still be affected by treatment such as
chemotherapy, completed several weeks before screening. The
authors recognise that possible treatment associated symptoms
may resolve before or after this time.
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